Urgent.News

What's breaking now, across thousands of outlets.

Health & Medicine

Hepatitis B could surge, infecting millions more in childhood, under proposed CDC guidance

A proposed shift in recommendations for hepatitis B vaccination in the U.S. could leave millions of young adults unprotected, a new modeling study suggests.

Hepatitis B could surge, infecting millions more in childhood, under proposed CDC guidance

A new modeling study predicts that a proposed change to CDC guidance on hepatitis B vaccination could lead to a significant increase in chronic HBV infections among young people in the United States. Currently, the CDC recommends universal birth-dose vaccination for all newborns within hours of birth, but the Advisory Committee on Immunization Practices (ACIP) recently advised ending this recommendation.

The CDC accepted this advice and now proposes that birth doses of the vaccine be given only to babies whose mothers are positive for HBV or whose status is unknown. Mothers who test negative are advised to discuss with their doctors whether their child needs a birth dose. The modeling study predicts that if this change were implemented, there would be a 19% increase in chronic HBV infections by age 20 among babies born in 2026 compared to universal birth-dose vaccination.

This would translate to approximately 1.8 million additional cases of chronic HBV infections among young adults, increasing the risk of liver scarring, liver cancer, and other chronic liver diseases. The study emphasizes that the birth-dose strategy is more effective in preventing chronic HBV infections than the proposed shared clinical decision-making approach.

Written by urgent.news from Live Science's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.

Read the original at livescience.com →

More in Health & Medicine

Bonjour Genomics: A Video from ASHG

GEN editors Uduak Thomas and Julianna LeMieux, PhD, recap ASHG, highlighting key sessions, Ultima Genomics’ user group meeting, Illumina news, and insights from PacBio’s new CEO Mark Van Oene.

More from Tuesday 27 October →